Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia

Karel Pavelka, Ruben Burgos-Vargas, Pedro Miranda, Renato Guzman, Jeng Hsien Yen, Mustafa Al Izzi, Zoltan Szekanecz, Boxiong Tang, Annette Szumski, Sameer Kotak, Eustratios Bananis, Andrew S. Koenig, Ehab Y. Mahgoub, Mahboob U. Rahman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aims: We compared etanercept 50 mg once weekly (ETN50)/methotrexate versus etanercept 25 mg (ETN25)/methotrexate or biologic-free methotrexate after response to ETN50/methotrexate in moderate rheumatoid arthitis patients from central/eastern Europe, Latin America and Asia.

Methods: In a 36-week induction phase, methotrexate-resistant patients received ETN50/methotrexate. In a 52-week, double-blind phase, patients who achieved sustained Disease Activity Score in 28 joints low disease activity (LDA) were randomized to ETN50/methotrexate, ETN25/methotrexate or methotrexate.

Results: Sustained Disease Activity Score in 28 joints LDA was achieved in 85% at week 36. LDA was achieved in 83, 81 and 50% with ETN50/methotrexate, ETN25/methotrexate and methotrexate and remission in 66, 61 and 31%, respectively, at week 88 (p < 0.0001).

Conclusion: Etanercept/methotrexate therapy for 36 weeks effectively induced response in this moderate rheumatoid arthritis subpopulation. Conventional- and reduced-dose etanercept/methotrexate was significantly more effective over the subsequent 52 weeks than biologic-free therapy.

Original languageEnglish
Pages (from-to)415-430
Number of pages16
JournalInternational Journal of Clinical Rheumatology
Volume9
Issue number5
DOIs
Publication statusPublished - Oct 1 2014

Keywords

  • biologic
  • efficacy
  • etanercept
  • low disease activity
  • methotrexate
  • moderate rheumatoid arthritis
  • remission

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia'. Together they form a unique fingerprint.

  • Cite this

    Pavelka, K., Burgos-Vargas, R., Miranda, P., Guzman, R., Yen, J. H., Izzi, M. A., Szekanecz, Z., Tang, B., Szumski, A., Kotak, S., Bananis, E., Koenig, A. S., Mahgoub, E. Y., & Rahman, M. U. (2014). Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia. International Journal of Clinical Rheumatology, 9(5), 415-430. https://doi.org/10.2217/ijr.14.27